It hit a high above 270, I remember cause shorted more the day it was happening!
I would say anyone buying here and holding long term, pretty much any promising biotech stock, will make a fortune.
Also PBYI is only $15 from filling the big gap from a little over a year ago. Should be a great place to buy if it continues down to there. Although I think it's already a great time to buy it at 75
Sentiment: Strong Buy
Yes, the NSABP FB-7 results were to be out awhile back, but still nothing. It's beyond frustrating. As noted previously, it's not Puma's study or data, so they are beholden to the NSABP Foundation. In the parlance of the trade, Puma is but a "collaborator". Many remain optimistic that the data will be good, particularly the triplet arm, but we won't know until it prints.
On September 11, 2015, the record for the trial on clinicaltrials.gov was updated to reflect a "September 2015" estimated primary completion date (go to the site and search to see for yourself, if you care to). Because the results have been repeatedly pushed back, it's impossible to guess if yet another delay will follow. It is worth noting, in my view, that they adjusted the date from "August" to "September" when we were already 11 days into September. That would seem to indicate there was some expectation things would wrap up before the end of September--otherwise, why wouldn't you simply insert "October" or "November" into the record. The issue with that thesis and optimism is that we're quickly running out of days in September. We shall see.
On a different note, this weekend Puma (presumably CEO Auerback) is scheduled to discuss the ExteNET data further in San Francisco at the ASCO breast event (again, talk a look online at the site and abstract should you find it of interest). Although it will likely be a rehash of what is known, the company has said in no uncertain terms they will work to speak more clearly about the use and efficacy of prophylaxis loperamide in the prevention of diarrhea. With the recently released patient case study of a late stage, essentially homebound patient responding so well to neratinib (HER2-), they have another case-in-point argument (n+1 though here) of the safety concern for the drug. The patient's tumor shrunk and she was able to garden, travel abroad and experienced no diarrhea at all. Did I say "We shall see"? I think I did above.
On September 9, 2015, Puma Biotechnology, Inc. was advised of the issuance by the United States Patent and Trademark Office of a Notice of Allowance for U.S. Patent Application 11/883,474 titled "Method for Treating Gefitinib Resistant Cancer." The patent application includes claims for a method for treating gefitinib and/or erlotinib resistant cancer by administering an irreversible epidermal growth factor receptor (EGFR) inhibitor.
In my experience the stock only moves higher when the correct people are long the stock. Apparently this news caught the floor traders off guard and their friends and family are not in yet. We will have to wait until the correct folks are in, before the broker-dealers take their foot off of our throats and allow it to move higher.